Clinical trials: filgrastim, open to volunteers
Bladder Cancer
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with…
- Trial name
- NCT07232602
- Testing
- MK-3120, EV, Pembrolizumab
- Where
- 17 sites in United States, Chile and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)…
- Trial name
- NCT06520163
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 17 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
This phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab plus ponatinib in treating patients newly diagnosed with…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma
- Trial name
- NCT07224100
- Testing
- Cyclophosphamide, Doxorubicin, Etoposide
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
Acute Myeloid Leukemia
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to…
- Trial name
- NCT06536010
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Xiaotian